Cover Story
CEOCFO
Interview
Index &
Quotes
CEOCFO
Current Issue
Future
Features
Monthly
Analyst
Industry
Review
Analyst
Interviews
and Reports
Corporate
Financials
Archived
CEOCFO
Interviews
About
CEOCFO
interviews.com
Contact
& Ordering |
Ostex International - forming a bond
between treating Osteoporosis and making sure that the therapies are working
Healthcare
Medical Equipment & Supplies
NASD: OSTX
Ostex International, Inc.
T.A. Bologna
Chairman, President and
Chief Executive Officer
Interview conducted by:
Walter Banks
Co-Publisher
CEOCFOinterviews.com
May 2002
Company
Profile:
Ostex International, Inc. develops and commercializes products to make
"disease management a reality" with Osteoporosis being the first area of focus.
The Company's lead product, the OSTEOMARK® NTx test, now available in multiple test
formats, incorporates breakthrough and patented technology for the management and
treatment of osteoporosis.
The OSTEOMARK NTx Urine and Serum tests are commercially available and have become a
valuable tool used in the prevention and treatment of osteoporosis. In April 2000, the
Company launched the OSTEOMARK NTx Point-of-Care device for use in the physician's office.
Additionally, the NTx Point-of-Care device is now available for Rx Home-Use whereby a
physician provides a prescription for the patient to use the device at home under the
physician’s direction. All are proprietary tests that measures NTx (cross-linked
N-telopeptide), a molecule released into urine and serum during breakdown of bone
collagen. OSTEOMARK NTx is indicated as a quantitative measure of NTx, an indicator of
bone resorption (breakdown). Clinical research has demonstrated that elevated bone
resorption is the primary cause of age-related bone loss and that low bone mass often
results in osteopenia, the major cause of osteoporosis.
At menopause,
OSTEOMARK NTx Urine and Serum tests are used to measure current NTx levels, which are
compared to a reference range of normal. NTx results complement the measurement of bone
mineral density (BMD) by providing a more thorough clinical evaluation of bone status. NTx
results are used as an aid in predicting skeletal response (as measured by BMD) to
antiresorptive therapy and in monitoring bone resorption changes following initiation of
therapy. This indication is utilized by physicians to assist in the effort to prevent
and/or treat osteoporosis when prescribing antiresorptive (osteoporosis) therapy.
Now with the
availability of the completely disposable and quantitative OSTEOMARK NTx Point-of-Care
device, monitoring bone resorption changes following initiation of antiresorptive therapy
can be performed in the physician's office during the patient visit and the device will be
available for purchase from pharmacies under the direction of a physician. A significant
change in bone resorption can be measured as early as three months following therapy
initiation.
Ostex International is also in the later stages of development of a patented cartilage
breakdown test that is designed to determine if an individual is at risk for
osteoarthritis and, if so, determine if treatment for the disease is working.
Interview
Highlights:
- Which disease is the current focus for their products?
- What application are they looking at for the future and what are their R&D
breakthroughs?
- Do they produce products to diagnose diseases or products to manage diseases?
- Why are their products so important to patients and companies that produce products to
fight those diseases?
- How does their products work?
- How often will patients need to use their products and will they have a continual need?
- Who are the companies with the strongest interest in their products?
- How strong is your patent protection?
- Who are their partners?
- What gives them an edge on their competition?
- Does their products save time and help to reduce healthcare costs?
- Do they have FDA approved products for use in the Osteoporosis market place?
- What is their marketing and sales strategy?
- Do they have the right relationships to implement their strategy?
- What is their revenue model and has it been built around disposables?
- Do they manufacture their own products?
- How many manufacturing facilities do they have?
- Do they have the manufacturing facilities necessary to meet demand for their products?
- When will their new facility be up and running?
- What global markets are they targeting?
- What is the size of their market place?
- Which of their products is creating a great deal of excitement for future growth?
- Is their product close to being available for purchase at pharmacies?
- To date, where have they been generating their greatest revenues?
- Where did their technology originate and what was it based on?
- How have they built out their product pipeline?
- When did they go public?
- Would they be will to sell their company or are they looking to build it out through
acquisitions?
- Who recently acquired one of their products?
- Do they have the cash and or credit to continue to build out their business?
To
receive a copy of this highly informative interview, left click here: Contact & Ordering
disclaimer
|
